Skip to main content
SpringerLink
Log in
Book cover

Encyclopedia of Cancer pp 1–4Cite as

Crohn Disease

  • Living reference work entry
  • First Online:

  • 79 Accesses

Synonyms

Inflammatory Bowel Disease (also includes Ulcerative Colitis)-related Cancer; Nonprimary APC mutation Colorectal Cancer

Definition

Crohn’s disease (also: regional enteritis) and ulcerative colitis area chronic, inflammatory conditions of the gastrointestinal tract. Although the inflammation of the mucosa is usually episodic in nature, these Inflammatory bowel diseases (IBD) are associated with an increased risk of developing colorectal cancer. Inflammatory bowel disease well-managed patients suffering from IBD have an approximately two times higher chance for contracting CRC as the population at large.

Characteristics

Inflammatory bowel disease (IBD) patients, which include the two related conditions of Crohn’s disease and ulcerative colitis, have an increased risk of developing colorectal cancer (CRC) (Itzkowitz and Yio 2004). For patients with Crohn’s disease [CD], the excess risk for contracting CRC has been estimated at 1.9, whereas the risk for small bowel cancer is 27.1...

This is a preview of subscription content, log in via an institution.

References

  • Baan B, Dihal AA, Hoff E, Bos CL, Voorneveld PW, Koelink PJ, Wildenberg ME, Muncan V, Heijmans J, Verspaget HW, Richel DJ, Hardwick JC, Hommes DW, Peppelenbosch MP, van den Brink GR (2012) 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. Gut 61(12):1708–1715

    Article  CAS  PubMed  Google Scholar 

  • Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP, Richel DJ (2006) Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 27:2371–2382

    Article  CAS  PubMed  Google Scholar 

  • Brown WA, Farmer KC, Skinner SA, Malcontenti-Wilson C, Misajon A, O’Brien PE (2000) 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 45:1578–1584

    Article  CAS  PubMed  Google Scholar 

  • Chu EC, Chai J, Ahluwalia A, Tarnawski AS (2007) Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment Pharmacol Ther 25:1443–1449

    Article  CAS  PubMed  Google Scholar 

  • Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J (2000) Colorectal cancer prevention in ulcerative colitis: a case–control study. Aliment Pharmacol Ther 14(2):145–153

    Article  CAS  PubMed  Google Scholar 

  • Gong W, Lv N, Wang B, Chen Y, Huang Y, Pan W, Jiang B (2012) Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci 57(2):503–507

    Article  PubMed  Google Scholar 

  • Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287:G7–G17

    Article  CAS  PubMed  Google Scholar 

  • Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI (2005) Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 100:2724–2729

    Article  PubMed  Google Scholar 

  • Lindberg BU, Broomé U, Persson B (2001) Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 44(1):77–85

    Article  CAS  PubMed  Google Scholar 

  • Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C (2007) 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 132:221–235

    Article  CAS  PubMed  Google Scholar 

  • Monteleone G, Franchi L, Fina D, Caruso R, Vavassori P, Monteleone I et al (2006) Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 13:202–221

    Article  CAS  PubMed  Google Scholar 

  • Munkholm P (2003) Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2):1–5

    Article  PubMed  Google Scholar 

  • Nguyen GC, Gulamhusein A, Bernstein CN (2012) 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 107(9):1298–1304

    Article  CAS  PubMed  Google Scholar 

  • Pinczowski D1, Ekbom A, Baron J, Yuen J, Adami HO (1994) Risk factors for colorectal cancer in patients with ulcerative colitis: a case–control study. Gastroenterology 107(1):117–20

    Google Scholar 

  • Reinacher-Schick A, Seidensticker F, Petrasch S, Reiser M, Philippou S, Theegarten D et al (2000) Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 32:245–254

    Article  CAS  PubMed  Google Scholar 

  • Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR (2013) Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case–control study. Clin Gastroenterol Hepatol 11(12):1601–8.e1–1601–8.e4

    Article  Google Scholar 

  • Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB (2006) Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 4(11):1346–1350

    Article  CAS  PubMed  Google Scholar 

  • Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126(2):451–459

    Article  PubMed  Google Scholar 

  • Schroeder KW (2002) Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand J Gastroenterol Suppl 236:42–47

    Article  PubMed  Google Scholar 

  • Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O et al (2008) PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 29:1407–1414

    Article  CAS  PubMed  Google Scholar 

  • Stolfi C, Fina D, Caruso R, Caprioli F, Fantini MC, Rizzo A et al (2008) Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis 29:1258–1266

    Article  CAS  PubMed  Google Scholar 

  • Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ (2006) Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case–control study. Gastroenterology 130(7):1941–1949

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713, Groningen, The Netherlands

    Gerard Dijkstra

  2. Erasmus Medical Center2, University Medical Center Rotterdam, Rotterdam, The Netherlands

    Maikel P. Peppelenbosch

Authors
  1. Gerard Dijkstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maikel P. Peppelenbosch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maikel P. Peppelenbosch .

Editor information

Editors and Affiliations

  1. Abt. Tumorgenetik, Deutsches Krebsforschungszentrum, Heidelberg, Germany

    Manfred Schwab

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Dijkstra, G., Peppelenbosch, M.P. (2015). Crohn Disease. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_1379-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-27841-9_1379-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Online ISBN: 978-3-642-27841-9

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation